ABI
ILMN icon

Adamant Biomedical Investments’s Illumina ILMN Stock Holding History

Adamant Biomedical Investments’s Portfolio ILMN Stock Details ILMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$7.38M Sell
41,120
-3,084
-7% -$543K 1.76% 18
2014
Q3 		$7.05M Buy
+44,204
New +$7.39M 1.76% 17

Other funds holding ILMN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Adamant Biomedical Investments's ILMN Position: Q4 2014 in Review

Adamant Biomedical Investments reduced its Illumina (ILMN) stake by 7% in Q4 2014, selling an estimated $543K and leaving 41,120 shares worth $7.38M. The position accounts for 1.76% of the portfolio, ranked #18.

Adamant Biomedical Investments first reported a position in ILMN in Q3 2014 and has held it in 2 quarters since. 531 funds tracked by Wall St. Rank hold ILMN as of Q4 2014.

  • Adamant Biomedical Investments held 41,120 shares of Illumina worth $7.38M as of Q4 2014.
  • Adamant Biomedical Investments sold 3,084 Illumina shares in Q4 2014, an estimated $543K.
  • Illumina made up 1.76% of Adamant Biomedical Investments's portfolio in Q4 2014, its #18 holding.
  • Adamant Biomedical Investments first reported a position in Illumina in Q3 2014 and has held it in 2 quarters since.
  • 531 funds tracked by Wall St. Rank held Illumina as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.